ABSTRACT

Introduction: It is well known that the malignant pleural mesothelioma (MPM) is refractory to treatment. The treatment only improves the symptoms and prolongs the life. The survival from the diagnosis is 4-16 months, depending on the mesothelioma type. Objective: This is a review of the treatment and the median survival time of patients that were treated at the Institute. Material and methods: A retrospective study in 90 patients who were treated from January 2006 to December 2009 was done. Sex, age, histological type, performance status (ECOG), stage (UICC/AJCC), treatment with Cisplatin/Pemetrexed (C/P). Cisplatin/Vinorelbine (C/V) y Cispatin/Epirubicin (C/E), and median overall survival (SGM) were registered. Results: 84 (93.3%) patients had epithelioid mesothelioma and in 6 (6.6%) sarcomatous or mixed mesothelioma were diagnosed; there were 68 male and 22 female, whose had ECOG 1 in 50 (55.5%) and stage III-IV in 53 (58.8%). At the first phase of treatment, all the patients received 6 cycles of QT and the response was evaluated as: 41 (45.5%) had partial response, 25 (27.6%) had progressive disease and 24 (26.6%) were death. At the second treatment, 46 patients received 4 to 6 cycles of a second line of QT, and 20 patients multimodal treatment: QT, pleuro neumonectomy with mediatinal linfadenectomy and RT in two cases. In this group, one patient had empiema, one bronchial fistula and one brain matastasis. The index QT/SGM showed: C/P 15.1 months, C/E 14.6 months, C/V 14.3 months. Patients with multimodal treatment had a greater survival: one had 40 months and another one, with 48 months, when the study was finished. Conclusions: The chemotherapy with C/V or C/E was similar as C/P. Multimodal chemotherapy resulted in greater survival.

KEYWORDS

Chemotherapeutic, immunohistochemistry, extrapleural neumonectomy, tumor progression.

REFERENCES

1. Robinson BW, Musk AW, Lake RA. Malignant mesothelioma. Lancet 2005;366(9483):397-408.

2. Corson JM. Pathology of mesothelioma. Thorac Surg Clin 2004;14(4):447-460.

3. Churg A, Cagle PT, Roggli VL. Tumors of the serosal membranes. Atlas of tumor pathology. 4th series, fascicle 3. Washington, DC: American Registry of Pathology; 2006.

4. Husain AN, Colby TV, Ordonez NG, Krausz T, et al. Guidelines for Pathologic Diagnosis of Malignant Mesothelioma: 2012 Update in Consensus from the International Mesothelioma Interest Group. Archives of Pathology & Laboratory Medicine, 2012.

5. Rusch VW. A proposed new international TNM staging system for malignant pleural mesothelioma. From the International Mesothelioma Interest Group. Chest 1995;108(4):1122-1128.

6. Tsao AS, Wistuba I, Roth JA, Kindler HL. Malignant pleural mesothelioma. J Clin Oncol 2009;27(12):2081-2090. doi: 10.1200/JCO.2008.19.8523.

7. Burdorf A, Barendregt JJ, Swuste PH, Heederik DJ. Increasing incidence of mesothelioma in the future by professional exposure to asbestos in the past. Dutch J Med 1997;141:1093-1098.

8. Echegoyen CR. Epidemiología clínica del mesotelioma pleural maligno en el INER. Neumol Cir Torax 2012;71(3):219-225.

9. Ellis P, Davies AM, Evans WK, Haynes AE, Lloyd NS; Lung Cancer Disease Site Group of Cancer Care Ontario’s Program in Evidence-based Care. The use or chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline. J Thorac Oncol 2006;1(6):591-601.

10. Ong ST, Vogelzang NJ. Chemotherapy in malignant pleural mesothelioma. A review. J Clin Oncol 1996;14(3):1007-1017.

11. Ceresoli G, Zucali P, Favaretto A, et al. Phase II study of pemetrexed plus carboplatin in malignant pleural mesothelioma. J Clin Oncol 2006;24(9):1443-1448.

12. Vogelzang NJ, Rusthoven JJ, Symanowski J, et al. Phase III study of pemetexed in combination with cisplatin versus cisplatin alone in patients with malignant pleural mesothelioma. J Clin Oncol 2003;21(14):2636-2644.

13. Jassem J, Ramlau R, Santoro A, et al. Phase III trial of pemetrexed plus best supportive care compared with best supportive care in previously treated patients with advanced malignant pleural mesothelioma. J Clin Oncol 2008;26(10):1698-1704. doi: 10.1200/JCO.2006.09.9887.

14. Planting AS, van der Burg ME, Goey SH, et al. Phase II study of a short course of weekly high-dose cisplatin combined with long-term oral etoposide in pleural mesothelioma. Ann Oncol 1995;6(6):613-615.

15. Sahmoud T, Postmus PE, van Pottelsberghe C, et al. Etoposide in malignant pleural mesothelioma; two phase II trials of the EORTC Lung Cancer Cooperative Group. Eur J Cancer 1997;33(13):2211-2215.

16. Castagneto B, Zai S, Dongiovanni D, et al. Cisplatin and gemcitabine in malignant pleural mesothelioma: a phase II study. Am J Clin Oncol 2005;28(3): 223-226.

17. Steele JP, Shamash J, Evans MT, Gower NH, Tischkowitz MD, Rudd RM. Phase II study of vinorelbine in patients with malignant pleural mesothelioma. J Clin Oncol 2000;18(23):3912-3917.

18. Shepherd FA1, Rodrigues Pereira J, Ciuleanu T, et al.; National Cancer Institute of Canada Clinical Trials Group. Erlotinib in previously treated non small cell lung cancer. N Engl J Med 2005;353(2):123-132.

19. Bareschino MA, Schettino C, Troiani T, Martinelli E, Morgillo F, Ciardiello F. Erlotinib in cancer tratment. An Oncol 2007;18 Suppl 6:vi35-41.

20. Tan C, Sedrakyan A, Browne J, Swift S, Treasure T. The evidence on the effectiveness of management for malignant pleural effusion: a systematic review. Eur J Cardio.Thorac Surg 2006;29:829-838.

21. Garland L, Flores R, Tsao A. Individualizing mesothelioma treatment: small steps into a brighter future. Clin Lung Cancer 2010;11(6):371-383. doi: 10.3816/CLC.2010.n.048.

22. De Perrot M, Uy K, Anraku M, et al. Impact of lymph node metastasis on outcome after extrapleural pneumonectomy for malignan pleural mesothelioma. J Thorac Cardiovasc Surg 2007;133(1):111-116.

23. Stahel R, Weder W. Neoadjuvant chemotherapy in malignant pleural mesothelioma. Lung Cancer 2005;49 Suppl 1:S69-70.

24. Weder W, Kestenholz P, Taverna C, et al. Neoadjuvant chemotherapy followed by extrapleural pneumonectomy in malignant pleural mesothelioma. J Clin Oncol 2004;22(17):3451-3457.

25. Echegoyen CR, Camacho MC. Calidad de vida y cáncer pulmonar. Neumol Cir Torax 2011;70(3):172-178.